Abstract
Hematological malignancies originating from blood, bone marrow, and lymph nodes include leukemia, lymphoma, and myeloma, which necessitate the use of a distinct chemotherapeutic approach. Drug resistance frequently complicates their treatment, highlighting the need for predictive tools to guide therapeutic decisions. Conventional 2D/3D cell cultures do not fully encompass in vivo criteria, and translating disease models from mice to humans proves challenging. Organ-on-a-chip technology presents an avenue to surmount genetic disparities between species, offering precise design, concurrent manipulation of various cell types, and extrapolation of data to human physiology. The development of bone-on-a-chip (BoC) systems is crucial for accurately representing the in vivo bone microenvironment, predicting drug responses for hematological cancers, mitigating drug resistance, and facilitating personalized therapeutic interventions. BoC systems for modeling hematological cancers and drug research can encompass intricate designs and integrated platforms for analyzing drug response data to simulate disease scenarios. This review provides a comprehensive examination of BoC systems applicable to modeling hematological cancers and visualizing drug responses within the intricate context of bone. It thoroughly discusses the materials pertinent to BoC systems, suitable in vitro techniques, the predictive capabilities of BoC systems in clinical settings, and their potential for commercialization.
Overview
- The study focuses on developing bone-on-a-chip (BoC) systems to accurately represent the in vivo bone microenvironment and predict drug responses for hematological cancers.
- The study uses organ-on-a-chip technology to overcome genetic disparities between species and provide precise design and manipulation of various cell types.
- The primary objective of the study is to develop a predictive tool for guiding therapeutic decisions in hematological cancer treatment, particularly in addressing drug resistance and implementing personalized interventions.
Comparative Analysis & Findings
- BoC systems offer a precise representation of the in vivo bone microenvironment, enabling accurate prediction of drug responses and mitigation of drug resistance in hematological cancer treatment.
- The study discusses the importance of intricate designs and integrated platforms for analyzing drug response data to simulate disease scenarios and improve treatment outcomes.
- BoC systems have the potential to be commercialized and become a valuable tool for predicting drug responses in clinical settings.
Implications and Future Directions
- The study highlights the potential of BoC systems in improving treatment outcomes for hematological cancers by providing accurate predictions of drug responses and personalized interventions.
- Future studies should focus on further developing and refining BoC systems to enhance their predictive capabilities in clinical settings.
- The study suggests that BoC systems could be integrated into standard treatment protocols for hematological cancers, providing a more personalized and effective treatment approach.